In conclusion, our study demonstrates the value of determining the expression of multiple proteins as readout for PI3K/MAPK pathway activation to predict adjuvant tamoxifen benefit in an ER+/HER2– breast cancer cohort. The gene discussed is ERBB2; the disease is breast cancer.